OBJECTIVES : The objective of the study was to explore the Indian pharmaceutical market for anti-cancer therapy targeting the various types of Glioma’s, to identify the standard of care, analyse competitive price landscape, and Price regulatory environment. We also set out to identify the future market potential for Glioma's.

METHODS : A PICO designed search string was used to obtain relevant studies. Munshi et al was used to classify Glioma's based on Histopathology, Tumor Grading and physical site. Further, the standard of care was identified using using grey literature search and public price data sets was used to analyse prices of competing brands. To identify the treatment options that are price regulated the latest update of the National List of Essential Medicines (NLEM) was used.

RESULTS : Based on the tumor type either one (or a combination of) surgery, radiation therapy, chemotherapy and Immunotherapy is recommended. Monoclonal antibodies approved for Glioma includes Nimotuzumab (9000₹/mg), and Bevacuzumab (1400₹/mg). Most preferred chemotherapeutic agent is Timozolamide (avg:12.25₹/mg, SD:11.17). Others include Cyclophosphamide, Etoposide, Everolimus, Lomustine, and Methotrexate. A targeted drug delivery system for Chemotherapy Agents used is Gliadel wafer (Polifeprosan 20 with Carmustine). An analysis of the price regulation revealed that four of the above mentioned chemotherapeutic agents are price capped (Timozolamide, Cyclophosphamide, Etoposide and Methotrexate).

CONCLUSIONS : The Glioma market is expected to increase to $3.3 billion by 2024, at a CAGR of 17.4%. But currently a large group of patients remain untapped and do not receive medical treatment. If this scenario prevails then neither the patient nor the manufacturer can benefit. Oncology market holds a lion's share of the therapeutic segment of India. This market is predicted to rise in the coming years but due to certain resisting forces like low affordability, unorganized healthcare services/insurance and price regulation, the growth cannot be at the predicted rate.